EPCS creates risk when security controls are bolted on without considering clinical use. The DEA requires certified systems, pharmacy approval and two factor authentication because controlled substances carry diversion and abuse risk. At the same time, poorly designed workflows slow clinicians and encourage bypasses. Effective programmes balance compliance with usability so the control framework is actually used in practice.
Why EPCS Needs Both Rulemaking and Workflow Design
EPCS is not just an access-control problem, it is a safety and adoption problem. Regulatory requirements set the minimum trust bar for controlled substances, while workflow design determines whether clinicians can complete prescribing without creating friction that leads to workarounds. The control only protects patients and reduces diversion when the security model fits the clinical process.
A regulatory baseline is necessary because e-prescribing for controlled substances changes the abuse and diversion profile of medication access. That is why certified systems, pharmacy acceptance, and stronger authentication are treated as mandatory control points rather than optional features. The technical and legal requirements establish who may prescribe, how authenticity is proven, and what must be auditable when controlled medications are involved.
Workflow design matters because clinicians do not experience EPCS as a policy document, they experience it as a task inside a busy care pathway. If the control adds too many steps, interrupts prescribing at the wrong moment, or creates inconsistent exceptions, users will search for faster routes around it. Good design therefore aligns the control with actual prescribing behaviour, rather than assuming users will adapt to the control as written.
Where Compliance Alone Fails in Clinical Operations
Regulatory oversight answers the question of whether the system is trustworthy enough to be used for controlled substances, but it does not answer whether the process is usable in the real world. A secure prescribing platform can still fail if clinicians encounter unnecessary delays, repeated reauthentication, poorly timed prompts, or confusing handoffs between prescriber, signer, and pharmacy. In practice, weak usability becomes a control failure because it encourages bypasses, informal delegation, or delayed prescribing.
The most common failure mode is treating security as a gate added after the workflow is already fixed. When that happens, the team optimises for technical compliance and leaves the user journey brittle. Healthcare identity controls work better when access, authentication, and approval steps are designed around clinical roles and prescribing moments, not bolted on as an afterthought, as discussed in the Healthcare Identity Security Guide.
That same pattern appears in broader control design guidance: the control must be strong enough to resist diversion, but simple enough that users keep using it under time pressure. For a prescriber, the right question is not only “is this compliant?” but “does this preserve the intended behaviour without creating a shortcut path?”
How to Balance Security, Usability, and Auditability
The practical goal is to keep the control framework visible, reliable, and minimally disruptive. That usually means the system should support a stable prescribing path, strong authentication at the point of material risk, and audit records that are usable for exception review and investigations. If prescribers need repeated exceptions just to finish routine work, the design has already lost some of its preventive value.
For regulated controlled substances, the operational design should make it easy to do the right thing and hard to do the risky thing. The CISA Secure by Design guidance is relevant here because the same principle applies: secure defaults and predictable flows matter more than adding security checks that users can only survive by bypassing.
Where workflow, identity, and privilege intersect, least-privilege access and strong authentication need to be embedded in the prescribing journey, not separated from it. Controls that are too generic for the clinical role create avoidable friction; controls that are too weak create diversion risk. The design target is a process that is both reviewable and operationally realistic.
Risk and Threat Considerations
When EPCS controls are implemented as a compliance overlay rather than a workflow-native control, organisations can end up with both security exposure and operational drift. The risk is not only theft or diversion of controlled substances, but also the gradual normalisation of bypasses, shared credentials, and weak exception handling when staff are under pressure.
Failure mechanism: Overly rigid or poorly timed security steps push users toward workarounds, while weakly integrated approval logic makes it easier for an attacker or insider to exploit exceptions, shared access, or process gaps.
Impact: The organisation can lose both the audit value of the control and the preventive value of the workflow, increasing diversion risk, reducing accountability, and making abnormal prescribing harder to detect.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
NIST SP 800-53 Rev 5 and CIS Controls v8 set the technical controls, while ISO/IEC 27001:2022 defines the regulatory obligations.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST SP 800-53 Rev 5 | IA-2 — Identification and Authentication (Organizational Users) | EPCS prescriber access depends on strong user authentication. |
| AC-6 — Least Privilege | EPCS workflows should limit prescribing authority to necessary roles. | |
| Recommendation — Enforce strong prescriber authentication before controlled-substance signing. Limit prescribing privileges to the minimum needed for the role. | ||
| ISO/IEC 27001:2022 | A.5.15 — Access control | EPCS requires controlled access to prescribing functions and exceptions. |
| Recommendation — Define and enforce access rules for EPCS functions and approvals. | ||
| CIS Controls v8 | CIS-5 — Account Management | EPCS depends on correct account ownership, role assignment, and lifecycle control. |
| Recommendation — Review prescribing accounts and remove unnecessary access promptly. | ||
Practitioner Guidance
What to prioritise: Design the prescribing flow around the clinical task first, then place the regulatory control points where they add assurance without forcing routine bypass behaviour. If a step is critical for controlled substances, it should be unambiguous and hard to circumvent; if it is not critical, do not let it create avoidable friction.
What to verify: Test the full prescriber journey in realistic conditions, including logging in, signing, canceling, correcting, and escalating prescriptions. The control is not trustworthy until you can show that clinicians can complete those tasks without resorting to workarounds or informal help from others.
Practitioner takeaway: EPCS succeeds when compliance and usability are designed as one control system, because a control that clinicians cannot tolerate will eventually be bypassed, and a control that is too weak will not protect against diversion.
Related resources from NHI Mgmt Group
- What is the difference between human IAM controls and NHI governance?
- When should organizations review access controls?
- How should hospitals design identity controls for clinicians without creating workflow friction?
- How should organisations design an electronic signature workflow to reduce signing friction without weakening assurance?
Deepen Your Knowledge
Reviewed and updated by the NHIMG editorial team on September 28, 2026.
NHI Mgmt Group — the #1 independent authority on Non-Human Identity, IAM, and Agentic AI security. nhimg.org
